Allergan’s International Business Segment in Q2 2018


Aug. 20 2018, Updated 9:31 a.m. ET

International Business segment

Allergan’s (AGN) International Business segment includes the revenues from both its specialized therapeutics portfolio and its general products portfolio from outside US markets.

The chart above compares the revenues for the International Business segment since the first quarter of 2017.

Article continues below advertisement

International Business segment

The International Business segment reported revenue of $949 million in the second quarter. The performances of each of the franchises in the segment in the quarter were as follows:

  • The eye care franchise reported a 9.8% rise in YoY (year-over-year) revenue to $353.7 million driven by strong sales of Lumigan/Ganfort, Ozurdex, Alphagan/Combigan, and Optive.
  • The medical esthetics franchise reported a 14.4% rise in YoY revenue to $409.8 million.
  • The facial esthetics portfolio reported a 14.7% rise in YoY revenue to $329.8 million. The facial esthetics portfolio includes Botox cosmetic products, Juvederm products, Kybella, Latisse, and other facial esthetics products.
  • Plastic surgery products reported a 2.9% fall in YoY revenue to $40.3 million. The plastic surgery portfolio includes breast augmentation products, implants, and breast reconstruction products.
  • Skincare products reported a 51.9% rise in YoY revenue to $4.1 million.
  • Regenerative medicines reported a 30.6% rise in revenue to $4.7 million.
  • Body contouring products reported a 36% rise in revenue to $30.9 million.
  • Botox therapeutics and other products, including Asacol and Constella, reported a 10.3% rise in YoY revenue to $166.6 million.

The First Trust NASDAQ Pharmaceuticals ETF (FTXH) holds 2.5% of its total investments in Allergan, 3.6% in AbbVie (ABBV), 3.7% in Mylan NV (MYL), and 4.0% in Johnson & Johnson (JNJ).


More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market RealistLogo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.